Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma.

by Annette Pflugfelder, Thomas K Eigentler, Ulrike Keim, Benjamin Weide, Ulrike Leiter, Kristian Ikenberg, Mark Berneburg, Claus Garbe
Published 2011-01-01

Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma.

by Maria Rita Gaiser, Alexander Skorokhod, Diana Gransheier, Benjamin Weide, Winfried Koch, Birgit Schif, Alexander Enk, Claus Garbe, Jürgen Bauer
Published 2017-01-01

The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma

by Bianca Simon, Manuel Wiesinger, Johannes März, Kilian Wistuba-Hamprecht, Benjamin Weide, Beatrice Schuler-Thurner, Gerold Schuler, Jan Dörrie, Ugur Uslu
Published 2018-08-01

Prognosis of sentinel node staged patients with primary cutaneous melanoma.

by Otmar Elsaesser, Ulrike Leiter, Petra G Buettner, Thomas K Eigentler, Friedegund Meier, Benjamin Weide, Gisela Metzler, Helmut Breuninger, Claus Garbe
Published 2012-01-01

Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis.

by Benjamin Weide, Christine Faller, Petra Büttner, Annette Pflugfelder, Ulrike Leiter, Thomas Kurt Eigentler, Jürgen Bauer, Andrea Forschner, Friedegund Meier, Claus Garbe
Published 2013-01-01

Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and prim...

by Benjamin Weide, Christine Faller, Margrit Elsässer, Petra Büttner, Annette Pflugfelder, Ulrike Leiter, Thomas Kurt Eigentler, Jürgen Bauer, Friedegund Meier, Claus Garbe
Published 2013-01-01

BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.

by Diana Meckbach, Ulrike Keim, Sabina Richter, Ulrike Leiter, Thomas K Eigentler, Jürgen Bauer, Annette Pflugfelder, Petra Büttner, Claus Garbe, Benjamin Weide
Published 2014-01-01

Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy.

by Benjamin Weide, Sabina Richter, Petra Büttner, Ulrike Leiter, Andrea Forschner, Jürgen Bauer, Laura Held, Thomas Kurt Eigentler, Friedegund Meier, Claus Garbe
Published 2013-01-01

Immune Signatures and Survival of Patients With Metastatic Melanoma, Renal Cancer, and Breast Cancer

by Kilian Wistuba-Hamprecht, Kilian Wistuba-Hamprecht, Cécile Gouttefangeas, Cécile Gouttefangeas, Cécile Gouttefangeas, Cécile Gouttefangeas, Benjamin Weide, Graham Pawelec, Graham Pawelec, Graham Pawelec
Published 2020-06-01

Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade.

by Jonas Bochem, Henning Zelba, Teresa Amaral, Janine Spreuer, Daniel Soffel, Thomas Eigentler, Nikolaus Benjamin Wagner, Ugur Uslu, Patrick Terheyden, Friedegund Meier, Claus Garbe, Graham Pawelec, Benjamin Weide, Kilian Wistuba-Hamprecht
Published 2019-01-01

Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma.

by Diana Meckbach, Jürgen Bauer, Annette Pflugfelder, Friedegund Meier, Christian Busch, Thomas K Eigentler, David Capper, Andreas von Deimling, Michel Mittelbronn, Sven Perner, Kristian Ikenberg, Markus Hantschke, Petra Büttner, Claus Garbe, Benjamin Weide
Published 2014-01-01

Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

by Nikolaus B. Wagner, Benjamin Weide, Mirko Gries, Maike Reith, Kathrin Tarnanidis, Valerie Schuermans, Charlotte Kemper, Coretta Kehrel, Anne Funder, Ramtin Lichtenberger, Antje Sucker, Esther Herpel, Tim Holland-Letz, Dirk Schadendorf, Claus Garbe, Viktor Umansky, Jochen Utikal, Christoffer Gebhardt
Published 2019-12-01

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

by Joanna Mangana, Phil F Cheng, Katja Schindler, Benjamin Weide, Ulrike Held, Anna L Frauchiger, Emanuella Romano, Katharina C Kähler, Sima Rozati, Markus Rechsteiner, Holger Moch, Olivier Michielin, Claus Garbe, Axel Hauschild, Christoph Hoeller, Reinhard Dummer, Simone M Goldinger
Published 2015-01-01

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions

by Antje Sucker, Fang Zhao, Natalia Pieper, Christina Heeke, Raffaela Maltaner, Nadine Stadtler, Birgit Real, Nicola Bielefeld, Sebastian Howe, Benjamin Weide, Ralf Gutzmer, Jochen Utikal, Carmen Loquai, Helen Gogas, Ludger Klein-Hitpass, Michael Zeschnigk, Astrid M. Westendorf, Mirko Trilling, Susanne Horn, Bastian Schilling, Dirk Schadendorf, Klaus G. Griewank, Annette Paschen
Published 2017-05-01

The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis

by Mitchell S. Stark, Kerenaftali Klein, Benjamin Weide, Lauren E. Haydu, Annette Pflugfelder, Yue Hang Tang, Jane M. Palmer, David C. Whiteman, Richard A. Scolyer, Graham J. Mann, John F. Thompson, Georgina V. Long, Andrew P. Barbour, H. Peter Soyer, Claus Garbe, Adrian Herington, Pamela M. Pollock, Nicholas K. Hayward
Published 2015-07-01

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study

by Carola Berking, Thomas K Eigentler, Andrea Forschner, Georg Richtig, Erika Richtig, Stefan Diem, Benjamin Weide, Bernhard Klumpp, Claus Garbe, Lukas Flatz, Patrick Terheyden, Lydia Reinhardt, Friedegund Meier, Carmen Loquai, Ulrike Leiter, Van Anh Nguyen, Martin Röcken, Mirjana Ziemer, Nikolaus B Wagner, Max M Lenders, Kathrin Kühl, Fiona André, Milena Dudda, Natalie Ring, Chiara Ebel, Ramon Stäger, Caroline Zellweger, Roland Lang, Michael Paar, Philipp Gussek, Suzan H Stürmer, Susanne Kimeswenger, Angela Oellinger, Maximilian Gassenmaier, Amadeus Schraag, Wolfram Hoetzenecker, Johanna Mangana, Christoffer Gebhardt, Antonio Cozzio
Published 2021-05-01

A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

by Hans-Georg Rammensee, Karl-Heinz Wiesmüller, P. Anoop Chandran, Henning Zelba, Elisa Rusch, Cécile Gouttefangeas, Daniel J. Kowalewski, Moreno Di Marco, Sebastian P. Haen, Juliane S. Walz, Yamel Cardona Gloria, Johanna Bödder, Jill-Marie Schertel, Antje Tunger, Luise Müller, Maximilian Kießler, Rebekka Wehner, Marc Schmitz, Meike Jakobi, Nicole Schneiderhan-Marra, Reinhild Klein, Karoline Laske, Kerstin Artzner, Linus Backert, Heiko Schuster, Johannes Schwenck, Alexander N. R. Weber, Bernd J. Pichler, Manfred Kneilling, Christian la Fougère, Stephan Forchhammer, Gisela Metzler, Jürgen Bauer, Benjamin Weide, Wilfried Schippert, Stefan Stevanović, Markus W. Löffler
Published 2019-11-01